common
cold
one
preval
acut
ill
worldwid
implic
time
lost
employ
time
lost
adult
contract
two
four
cold
per
year
wherea
children
mani
cold
per
year
produc
substanti
expenditur
physician
offic
visit
overthecount
cold
cough
infect
selflimit
usual
resolv
within
day
mani
cold
persist
week
due
variou
virus
although
known
rhinoviru
infect
caus
coronaviru
parainfluenza
viru
adenoviru
echoviru
coxsacki
viru
account
remaind
virus
produc
clinic
indistinguish
make
specif
viral
diagnosi
difficult
avail
remedi
act
allevi
cold
symptom
sneez
nasal
stuffi
discharg
sore
scratchi
throat
cough
hoars
headach
fever
myalgia
true
therapeut
benefit
toward
elimin
viral
echinacea
member
composita
famili
herb
wide
use
treat
prevent
common
shown
immunostimulatori
three
nine
speci
famili
medicin
interest
echinacea
angustifolia
e
pallida
e
purpurea
commonli
use
treat
viral
upper
respiratori
tract
echinacea
caus
increas
number
circul
white
blood
cell
activ
phagocytosi
human
granulocyt
elev
bodi
result
primarili
aerial
portion
e
root
portion
e
previou
research
suggest
echinacea
may
effect
reduc
sever
durat
common
cold
taken
earli
littl
prevent
review
five
random
clinic
trial
investig
immunomodulatori
activ
echinacea
conclud
echinacea
may
efficaci
immun
garlic
allium
sativum
one
oldest
medicin
plant
use
differ
cultur
oldest
report
healthpromot
properti
garlic
date
back
centuri
bc
eber
papyru
egypt
ailment
purport
effici
cure
garlic
stimul
immun
system
act
natur
antibiot
harm
friendli
bacteri
flora
mani
laboratori
studi
confirm
antibacteri
antifung
antiviru
immunostimul
antioxid
properti
us
nation
cancer
institut
initi
design
food
program
determin
food
play
import
role
cancer
prevent
conclud
garlic
may
potent
food
cancerprevent
nigella
sativa
black
seed
refer
prophet
moham
heal
power
also
identifi
cur
black
cumin
holi
bibl
describ
melanthion
hippocr
discroid
gith
effect
n
sativa
immun
respons
evalu
human
volunt
result
show
black
seed
enhanc
ratio
helper
cell
suppressor
cell
averag
enhanc
natur
killer
nk
cell
n
sativa
also
establish
efficaci
sever
speci
pathogen
bacteria
staphylococcu
aureu
pseudomona
aeruginosa
pathogen
yeast
candida
albican
extract
american
ginseng
panax
quinquefolium
shown
immunomodulatori
extract
shown
enhanc
immun
respons
immunoglobulin
product
lymphocyt
natur
immun
respons
periton
exud
also
found
enhanc
anticomplementari
reticuloendotheli
system
enhanc
macrophag
fc
receptor
increas
phagocytosi
index
along
phagocytosi
induc
messeng
rna
express
interferongamma
granulocytemacrophag
colonystimul
factor
well
lymphokineactiv
killer
cell
addit
extract
appear
stimul
cellmedi
immun
respons
nk
cell
well
cytotox
effect
wide
rang
tumor
cell
line
without
major
histocompat
complex
ginseng
extract
found
effect
prevent
acut
respiratori
ill
due
influenza
respiratori
syncyti
viru
clinic
trial
involv
elderli
peopl
live
vitamin
c
ascorb
acid
watersolubl
vitamin
found
fruit
veget
particularli
citru
fruit
necessari
iron
absorpt
wound
heal
collagen
vitamin
c
also
recogn
import
success
product
neurotransmitt
improv
glucos
metabol
defici
result
neurolog
diseas
vitamin
c
associ
immun
strengthen
deriv
abil
enhanc
function
immun
system
includ
antimicrobi
nk
cell
activ
macrophag
lymphocyt
prolifer
chemotaxi
delayedtyp
zinc
salt
found
inhibit
rhinoviru
replic
vitro
concentr
possibl
interf
rhinoviru
protein
altern
suggest
zinc
salt
may
protect
plasma
membran
lysi
cytotox
agent
microbi
toxin
propos
protect
mechan
either
via
via
bind
zinc
ion
rhinoviru
surfac
canyon
thu
inhibit
viral
interact
intercellular
adhes
site
rhinoviru
bind
also
bind
site
leukocyt
function
associ
block
bind
postul
possibl
suppress
sever
random
control
clinic
studi
show
benefici
effect
use
zinc
treat
common
cold
particularli
zinc
start
within
first
hour
onset
immumax
manag
common
cold
immumax
product
beovitasaf
pharma
german
pharmaceut
compani
combin
natur
herbal
extract
includ
echinacea
extract
mg
garlic
powder
mg
nigella
sativa
oil
mg
panax
ginseng
extract
mg
plu
vitamin
c
mg
element
zinc
mg
multipl
immunomodulatori
activ
differ
level
proven
vitro
antivir
activ
encourag
us
studi
potenti
efficaci
toler
multiingredi
formula
treatment
human
patient
suffer
common
cold
studi
conduct
prospect
doubleblind
random
control
manner
outpati
set
patient
includ
cold
symptom
hour
less
patient
must
least
two
follow
symptom
cough
headach
hoars
muscl
ach
nasal
discharg
nasal
congest
scratchi
throat
sore
throat
sneez
oral
temperatur
patient
exclud
pregnant
known
immun
defici
cancer
sever
liverren
dysfunct
critic
ill
symptom
common
cold
hour
immumax
capsul
ident
placebo
capsul
contain
beeswax
pack
code
research
assist
blind
studi
particip
patient
fulfil
inclusionexclus
criteria
randomli
divid
two
treatment
group
experiment
group
start
treatment
immumax
dose
one
capsul
twice
daili
recoveri
symptom
maximum
day
control
group
took
one
placebo
capsul
twice
daili
regimen
random
done
use
softwaregener
block
random
techniqu
patient
investig
blind
alloc
drug
random
list
drug
code
lock
seal
envelop
end
followup
period
final
assess
statist
analysi
patient
given
similar
pack
capsul
ask
swallow
one
capsul
twice
daili
long
hesh
cold
symptom
first
capsul
administ
enrol
clinic
assess
initi
toler
particip
ask
take
cold
prepar
studi
period
apart
acetaminophen
symptomat
relief
pain
fever
asneed
basi
oral
thermomet
given
patient
time
enrol
patient
ask
revisit
day
start
treatment
within
day
note
cold
symptom
resolv
visit
return
unus
capsul
adher
protocol
could
check
capsul
count
treat
physician
could
confirm
cold
symptom
resolv
patient
ask
complet
daili
record
document
sever
symptom
medic
taken
throughout
durat
cold
long
day
everi
day
patient
grade
symptom
none
mild
moder
sever
total
symptom
score
calcul
sum
score
symptom
patient
day
cold
resolut
defin
resolut
symptom
total
symptom
score
resolut
one
mild
symptom
total
symptom
score
time
cold
resolut
calcul
number
day
studi
entri
summar
median
interquartil
rang
iqr
treatment
group
resolut
rate
estim
use
method
resolut
profil
compar
group
use
logrank
test
mean
percentag
chang
total
symptom
sever
score
day
baselin
compar
two
group
oneway
analysi
varianc
anova
chisquar
test
fisher
exact
test
use
analyz
associ
side
effect
assign
group
patient
consid
adher
took
averag
two
capsul
per
day
first
day
studi
eight
capsul
took
antibiot
agent
seventyf
patient
present
common
cold
symptom
assess
elig
criteria
nine
exclud
fulfil
elig
criteria
wherea
anoth
four
refus
sign
inform
consent
sixtytwo
patient
random
two
equal
group
patient
assign
immumax
group
remain
assign
placebo
group
one
patient
immumax
group
withdrew
studi
first
day
could
toler
capsul
see
figur
patient
directli
observ
studi
nurs
indic
good
toler
first
dose
baselin
characterist
two
group
given
tabl
incid
sever
individu
symptom
baselin
well
demograph
characterist
almost
similar
two
group
seven
patient
five
placebo
group
two
immumax
group
cold
report
resolv
followup
period
studi
censor
two
patient
placebo
recipi
complet
day
studi
remain
symptom
anoth
two
patient
placebo
group
report
condit
worsen
need
treat
antibiot
lower
respiratori
tract
bacteri
infect
remain
three
seven
censor
patient
lost
followup
two
immumax
group
one
placebotr
group
use
surviv
analysi
estim
percentag
patient
whose
cold
resolv
total
symptom
score
day
studi
figur
median
iqr
time
resolut
symptom
day
placebo
group
day
immumax
group
result
logrank
test
indic
symptom
resolv
significantli
faster
immumax
group
placebo
group
p
signific
differ
complianc
group
first
day
therapi
p
mean
percentag
reduct
total
symptom
sever
score
baselin
day
significantli
greater
immumax
group
placebo
group
oneway
anova
tabl
end
studi
eight
placebo
recipi
immumax
recipi
report
studi
medic
help
improv
cold
symptom
p
frequenc
report
advers
effect
includ
nausea
vomit
abdomin
pain
diarrhea
fatigu
dizzi
differ
significantli
two
group
knowledg
first
studi
test
effect
multiherb
prepar
vitamin
c
zinc
alreadi
consum
dietari
supplement
durat
sever
common
cold
symptom
indic
introduct
plethora
data
literatur
either
basic
clinic
studi
address
immunostimulatori
antivir
activ
opt
conduct
simpl
pilot
studi
pragmat
hypothesi
rather
confirmatori
explanatori
studi
opinion
altern
medicin
need
much
translat
research
clinic
trial
human
subject
perform
publish
scientif
literatur
especi
product
alreadi
consum
overthecount
dietari
supplement
author
admit
mani
limit
studi
includ
small
size
short
followup
period
depend
mainli
symptom
subject
score
outcom
measur
without
correl
find
object
laboratori
data
limit
explain
percept
studi
altern
medicin
due
lack
patent
protect
unlik
patent
new
chemic
entiti
fund
pharmaceut
industri
usual
suffer
financi
logist
constraint
conclud
studi
immumax
help
reduc
durat
sever
common
cold
symptom
confirmatori
explanatori
random
studi
need
confirm
